ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listen ...

In the latest market close, TransMedics (TMDX) reached $91.82, with no movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.2%. On the other hand, the Dow registered a loss of 0.65%, and the technology-centric Nasdaq decreased by 1.79%.Prior to today's trading, shares of the medical technology company had gained 20.91% over the past month. This has outpaced the Medical sector's loss of 6.57% and the S&P 500's loss of 0.85% in that time.Market participants ...

uchar/E+ via Getty Images Increasingly unhealthy lifestyles are leading to a higher incidence of organ failure worldwide, and while organ transplantation is generally the preferred treatment for organ failure due to better outcomes and quality of life, organ supply is currently heavily constrained for a variety of reasons, leading to a waiting list that as of 2023, numbers over 100,000 patients in the U.S. alone. American medtech company TransMedics’s (NASDAQ:TMDX) disruptive FDA-approved medical device ...

sturti TransMedics Group, Inc. (NASDAQ:TMDX), a company you probably never heard of, is transforming the organ transplant landscape. This is a rare opportunity to invest in a company that's going to save thousands of lives (and already has), at a very early stage, but with already proven capabilities and FDA approvals. Let's dive in. Introduction To TransMedics TransMedics Group was founded in 1998 by Dr. Waleed H. Hassanein. It is a medical technology company focused on transforming organ transplant therap ...

ANDOVER, Mass., Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 9:50 a.m. EST and to presen ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2023 Earnings Conference Call February 26, 2024 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group, IR Waleed Hassanein - President and CEO Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Bill Plovanic - Canaccord Ryan Daniels - William Blair Suraj Kalia - Oppenheimer & Company Operator Good afternoon. And welcome to the TransMedics Fourth Quarter and Full Year 2023 Earnings Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR (I.R.S. Employer Identification No.) 200 Minuteman Road Andover, Massachusetts 01810 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (978) 552-0900 Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT P ...

Fourth Quarter 2023 Financial Results Exhibit 99.1 Total revenue for the fourth quarter of 2023 was $81.2 million, a 159% increase compared to $31.4 million in the fourth quarter of 2022. The increase was due primarily to the increase in utilization of the OCS through the National OCS Program ("NOP") as well as additional revenue generated by the addition of TransMedics logistics services. TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results "2023 was a great year for TransMedics as we ac ...

Morsa Images Investment Thesis TransMedics Group, Inc. (NASDAQ:TMDX) is an underappreciated medical technology stock that's signature invention, the Organ Care System, helps better transport donor organs by keeping them in warm fluid that mimics the human body. The company has seen phenomenal growth, reporting 159% YoY and 27% QoQ revenue growth in its most recent Q3 2023 quarter. TransMedics is a 4% position for us. We were buyers in August-November 2023 with an average price of $59, but the stock ran up f ...

ANDOVER, Mass., Jan. 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 12, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 24,535 shares of its common stock and an aggregate of 15,817 restricted stock units to 16 employees, each as a material inducement for each employee's entry ...